1. Home
  2. Analysis
  3. Fludara
  4. Shock-haemorrhagic

Fludara and Shock haemorrhagic - a phase IV clinical study of FDA data

Summary:

Shock haemorrhagic is reported as a side effect among people who take Fludara (fludarabine phosphate), especially for people who are male, 40-49 old, have been taking the drug for < 1 month also take Cyclophosphamide, and have Bone marrow conditioning regimen.

The phase IV clinical study analyzes which people have Shock haemorrhagic when taking Fludara. It is created by eHealthMe based on reports of 46,669 people who have side effects when taking Fludara from the FDA, and is updated regularly.

What is Fludara?

Fludara has active ingredients of fludarabine phosphate. eHealthMe is studying from 46,686 Fludara users. Check the latest studies of Fludara.

What is Shock haemorrhagic?

Shock haemorrhagic (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin due to excess bleeding) is found to be associated with 657 drugs and 799 conditions by eHealthMe. Check the latest studies of Shock haemorrhagic.

On Jul, 05, 2026

46,669 people reported to have side effects when taking Fludara.
Among them, 78 people (0.17%) have Shock haemorrhagic.

Could Fludara cause Shock haemorrhagic?

Among these 78 people:

How long have people been on Fludara when they have Shock haemorrhagic? *

  • < 1 month: 100 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Shock haemorrhagic when taking Fludara? *

  • female: 48.39 %
  • male: 51.61 %

What is the age of people who have Shock haemorrhagic when taking Fludara? *

  • 0-1: 0.0 %
  • 2-9: 15.79 %
  • 10-19: 14.04 %
  • 20-29: 7.02 %
  • 30-39: 7.02 %
  • 40-49: 21.05 %
  • 50-59: 17.54 %
  • 60+: 17.54 %

What are other drugs people take besides Fludara? *

  1. Cyclophosphamide: 28 people, 35.90%
  2. Methotrexate: 19 people, 24.36%
  3. Cyclosporine: 17 people, 21.79%
  4. Defitelio: 12 people, 15.38%
  5. Mycophenolate Mofetil: 12 people, 15.38%
  6. Cytarabine: 11 people, 14.10%
  7. Busulfan: 10 people, 12.82%
  8. Dexamethasone: 10 people, 12.82%
  9. Acyclovir: 10 people, 12.82%
  10. Lansoprazole: 9 people, 11.54%

What are other side effects people have besides Shock haemorrhagic? *

  1. Fever: 21 people, 26.92%
  2. Venoocclusive Disease (small veins in the liver are obstructed): 15 people, 19.23%
  3. Thrombocytopenia (decrease of platelets in blood): 14 people, 17.95%
  4. Lactic Acidosis (low ph in body tissues): 12 people, 15.38%
  5. Rectal Haemorrhage (bleeding from anus): 12 people, 15.38%
  6. Haemorrhage (bleeding): 12 people, 15.38%
  7. Cytokine Release Syndrome (immediate complication occurring with the use of anti-t cell antibody infusions): 12 people, 15.38%
  8. Bleeding Disorders: 11 people, 14.10%
  9. Stomatitis (inflammation of mucous membrane of mouth): 11 people, 14.10%
  10. Hepatic Failure (liver failure): 10 people, 12.82%

What are the existing conditions these people have? *

  1. Bone Marrow Conditioning Regimen: 28 people, 35.90%
  2. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 13 people, 16.67%
  3. B-Cell Type Acute Leukaemia (cancer of the white blood cells): 12 people, 15.38%
  4. Venoocclusive Disease (small veins in the liver are obstructed): 6 people, 7.69%
  5. Venoocclusive Liver Disease (small veins in the liver are obstructed): 6 people, 7.69%
  6. Leukaemia Recurrent (repeat cancer of bone marrow or blood cells): 6 people, 7.69%
  7. Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 5 people, 6.41%
  8. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 5 people, 6.41%
  9. Immunodeficiency Disorders: 4 people, 5.13%
  10. Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 4 people, 5.13%

* Approximation only. Some reports may have incomplete information.

Do you take Fludara and have Shock haemorrhagic?

- Check whether Shock haemorrhagic is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fludara:

Shock haemorrhagic treatments and more:

How severe was Shock haemorrhagic and when was it recovered:

Expand to all the drugs that have ingredients of fludarabine phosphate:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Fludara:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Shock haemorrhagic:

Browse all the conditions that are associated with Shock haemorrhagic:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on fludarabine phosphate (the active ingredients of Fludara) and Fludara (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.